trial · primary record
Durvalumab
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 103 |
| Primary completion | 2028-01-05 |
| Primary endpoint | Progression-free survival (PFS) in randomized participants |
| Registry ID | NCT06008093 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:56.026Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06008093
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Durvalumab · approval
- Durvalumab · compound